Acrivon Therapeutics (ACRV) Corporate presentation summary

Strategic focus and technology platform

• AP3 platform leverages AI-driven proteomics for rational drug design and clinical development, enabling precise matching of drug mechanisms to disease-driving pathways in oncology and inflammation.

• Proprietary tools include a data portal, interactome, and protein activity predictor, supporting drug discovery and biomarker development.

• Headquarters in Boston with a proteomics hub in Medicon Valley, facilitating access to leading biotech resources.

• Founded in 2018, IPO in 2022, with a leadership team experienced in drug development, clinical trials, and business operations.

Pipeline and clinical programs

• Lead asset ACR-368 (CHK1/2 inhibitor) shows durable monotherapy activity and favorable safety in multiple cancers, with a focus on endometrial cancer.

• Phase 2b trial in serous endometrial cancer demonstrates 52% ORR in patients with ≤2 prior lines of therapy, significantly higher than historical controls.

• ACR-2316 (WEE1/PKMYT1 inhibitor) in Phase 1/2, designed for superior selectivity and therapeutic index, with durable activity in heavily pretreated lung cancer and other solid tumors.

• IND filing for a novel CDKII inhibitor anticipated in 1H 2027, with preclinical data showing complete AML tumor regression and synergy with BCL-2 inhibitors.

Biomarker and precision medicine capabilities

• AP3 enables OncoSignature biomarker tests to prospectively predict patient response, excluding non-responders and optimizing trial design.

• Newly licensed CLIA laboratory translates AP3-driven biomarker discoveries into proprietary companion diagnostics, initially supporting ACR-368.

• AP3 interactome and data portal provide machine learning-enabled pathway and biomarker analyses for all internal programs.